Gut bacteria and fatty liver disease study
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and its byproducts are linked to fatty liver disease (MAFLD). It compares people with the condition to healthy individuals to better understand the connection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are either a healthy person with no liver disease or you have been diagnosed with MAFLD (fatty liver disease with metabolic issues).
- If you have MAFLD, it must be confirmed by imaging (like ultrasound) or a liver biopsy showing at least 5% fat in your liver cells.
- You have at least one sign of metabolic syndrome, such as high blood pressure, high blood sugar, or abnormal cholesterol.
- You are over 18 years old.
- You agree to join the study and sign a consent form.
- You have not had a serious infection or taken antibiotics, probiotics, laxatives, or stomach acid reducers in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how common non-alcoholic fatty liver disease is in people with inflammatory bowel disease (Crohn's or colitis). Researchers want to learn more about the link between the two conditions.
This trial tests a natural substance called Calculus Bovis Sativus to see if it can help people with metabolic fatty liver disease (MAFLD). It aims to improve liver health and reduce fat in the liver.
This study looks at how lactate-related changes in gut bacteria might affect the progression of liver cirrhosis. It includes both healthy people and cirrhosis patients to see how these factors relate.
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
This study looks for a possible link between a common stomach bacteria (Helicobacter pylori) and a type of fatty liver disease called MAFLD. It may help explain if treating the infection could improve liver health.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.